
Diabetic cardiomyopathy (DCM), a diabetes-specific myocardial pathology, is a significant contributor to diabetes-related heart failure. Endoplasmic reticulum (ER) stress plays a crucial role in DCM, yet its upstream regulatory mechanisms remain incompletely elucidated. Cellular heterogeneity in DCM was investigated by analyzing single-cell transcriptomic data from the Gene Expression Omnibus. A mouse DCM model was established and validated using echocardiography, serum biochemical assays, and histological analysis. TNFAIP1 expression was detected by Western blot. A high glucose-induced DCM cellular model was constructed using HL-1 cardiomyocytes and neonatal cardiomyocytes (NMCMs). Cell injury and TNFAIP1 expression were assessed via TUNEL staining, Annexin V/PI staining, CellRox probe, RT-qPCR, and Western blot. Finally, a TNFAIP1-knockdown DCM mouse model was constructed, and the in vitro results were further validated by echocardiography, serum biochemical assays, histological analysis, and other methods. Single-cell analyses revealed the enrichment of TNFAIP1+ cardiomyocytes in DCM, with their differentially expressed genes enriched in p38 MAPK and apoptosis signaling pathways. TNFAIP1 expression was significantly upregulated in both DCM mouse and cellular models. TNFAIP1 overexpression activated p38 MAPK-mediated ER stress, increased ROS levels, and promoted apoptosis, whereas TNFAIP1 knockdown produced the opposite effects. These effects were significantly reversed by the p38 MAPK pathway inhibitor SB203580, the ER stress inhibitor TUDCA, and the ER stress inducer Thapsigargin. Finally, in vivo experiments further confirmed that TNFAIP1 knockdown ameliorated the progression of myocardial injury in DCM mice. TNFAIP1 promotes DCM progression via the p38 MAPK-mediated ER stress-apoptosis axis, identifying TNFAIP1 as a novel potential therapeutic target for DCM.
Background The Theory of Planned Behavior (TPB) posits that attitudes influence behavior through intentions, yet this pathway has not been thoroughly examined at the within-person level in the alcohol literature. This study tested whether daily fluctuations in attitudes toward heavy drinking predicted same-day alcohol-related consequences and alcohol-induced blackouts through a serial mediation involving daily drinking intentions and alcohol consumption.Methods Participants were 87 heavy-drinking young adults (53.4% female; Mage = 22.22 years) enrolled in the intervention arm of a randomized clinical trial who completed up to 30 consecutive days of morning diary assessments. Multilevel models separated within-and between-person variance by person-mean centering daily predictors. Serial mediation pathways were estimated using multilevel regression models, and specific indirect effects were tested using Monte Carlo confidence intervals.Results On days when participants reported more favorable attitudes toward heavy drinking than their own average, they also reported stronger intentions to drink, which predicted greater same-day alcohol consumption. Greater drinking, in turn, predicted increased odds of both alcohol-related consequences and blackout. Significant serial indirect effects supported the hypothesized pathway from attitudes to consequences and blackout through intentions and drinking. Drinking intentions also directly predicted alcohol-related consequences independent of drinking quantity but did not directly predict blackout after accounting for drinking, suggesting differences in the mechanisms underlying these outcomes.Conclusion Findings provide day-level support for a TPB-informed pathway linking within-person fluctuations in drinking attitudes to alcohol-related harm through drinking intentions and alcohol consumption. Results extend prior between-person TPB research by demonstrating that attitudes and intentions function as dynamic, day-to-day processes that help explain when individuals are at elevated risk for harmful drinking outcomes. Daily attitudes and intentions may represent promising targets for ecological momentary interventions designed to reduce alcohol-related harm.
Background Variation in gene expression is hypothesized to be a major source of phenotypic variation underlying the liability for alcohol misuse. Caenorhabditis elegans (C. elegans) has proven to be a valuable model in the identification of genes that modify behavioral responses to alcohol. Genetic variation in wild strains represents allelic differences that are tolerated by natural selection pressures and, therefore, are more likely to model the allelic differences that are present in humans compared with laboratory-generated mutations.Methods We examined the influence of natural alleles on gene expression in response to ethanol by mapping eQTL in C. elegans. We used a recombinant inbred panel derived from four wild strains to examine the regulation of ethanol exposure-induced gene expression. We performed differential gene expression analyses and mapped eQTL. Detailed examination of trans-bandChrV-0:3 Mb included quantification of the behavioral responses to ethanol for top candidate genes in the trans-band.Results Ethanol exposure increased trans-eQTL and decreased cis-eQTL. We observed the largest shift in distantly regulated transcripts on the first three Mb on chromosome V that contained 355 trans-eQTL in a single trans-band. The eQTL group in this trans-band was involved in processes implicated in alcohol use disorder and its gene ontology terms included unsaturated fatty acids, responses to stress and environment, and immune and defense responses. We validated this genomic region using an introgression line and identified nhr-131 and dod-19 as potential polymorphic modifiers of trans-bandChrV-0:3 Mb. We tested null mutations in nhr-131 and dod-19 and found that dod-19 is required for the normal development of acute functional tolerance (AFT) to ethanol.Conclusions Natural genetic variation in these wild strains primarily affected trans-regulated gene expression. Examination of trans-bandChrV-0:3 Mb identified dod-19 as a candidate expression modifier gene that regulates the development of AFT to ethanol and further implicates membrane biology in this process.
Murine research on atherosclerosis has been conducted largely on the C57BL/6 (B6) strain background, and most commonly, the B6.129P2-Apoe tm1Unc/J (B6-ApoEKO) strain. The use of the B6 background strain limits translatability for immunotherapy development due to inherent species differences between human and mouse immune systems. A proposed solution to this limitation is a humanized mouse model of atherosclerosis that would support the engraftment of human lymphoid and myeloid cell populations. The development of such a model has been hindered by the lack of a mouse strain that both develops atherosclerosis and supports human immune cell engraftment. In this paper, we report on a NOD.Cg-Prkdc scid Il2rg tm1Wjl/Sz (NSG) immunodeficient mouse strain that has a 383 bp deletion in the Apoe gene which prevents ApoE protein expression. When maintained on a high fat diet, NSG-ApoEKO mice develop hypercholesteremia and atherosclerosis at levels similar to B6-ApoEKO mice. While atherosclerosis in B6-ApoEKO mice has been widely studied in many laboratories under multiple conditions, our initial study of disease development in NSG-ApoEKO mice was limited and future comparative studies with B6-ApoEKO mice are necessary. NSG-ApoEKO mice concomitantly support human cell engraftment while developing atherosclerosis, thereby making them useful to study human-specific immune aspects.
Obesity and its associated metabolic disorders have become major global public health challenges. Increasing evidence indicates that mitophagy plays a pivotal role in the pathogenesis of obesity and related metabolic diseases. This study aimed to investigate the role and underlying mechanisms of E3 ubiquitin ligase RNF126 in obesity and non-alcoholic fatty liver disease (NAFLD). Using Rnf126 +/- mice fed a high-fat diet (HFD), we found RNF126 deficiency markedly exacerbated body weight gain, elevated serum ALT and AST levels, inflammatory responses, apoptosis, and insulin resistance. Histological analysis with H&E and Oil Red O staining revealed that RNF126 deficiency aggravated hepatic inflammatory cell infiltration, lipid droplet accumulation, and adipocyte hypertrophy in HFD-fed mice. HFD feeding significantly inhibited RNF126 expression in liver and muscle. Moreover, Rnf126 +/- mice exhibited reduced oxygen consumption, carbon dioxide production and heat generation without changes in food intake. Mechanistically, qPCR and Western blot analyses demonstrated that RNF126 deficiency suppressed the mRNA and protein expression of UCP-1, SIRT1, and PGC-1 alpha in the liver and white adipose tissue, indicating impaired mitochondrial biogenesis. Moreover, the protein levels of cleaved PINK1, Parkin, and LC3 were reduced, while p62 expression was increased in the liver of Rnf126 +/- mice, indicating inhibited autophagic activity. Consistently, oxidative stress was significantly elevated, as evidenced by increased MDA levels and decreased SOD and GSH contents. Rnf126 +/- mice livers displayed obvious mitochondrial swelling and partial cristae disorganization with an increase of mtDNA expression. Mitochondrial complex-III enzymatic activity, hepatic ATP, TOM20 protein expression and complex-III subunit UQCRFS1 expression were substantially decreased in HFD-fed Rnf126 +/- mice. At the cellular level, RNF126 overexpression in palmitic acid-treated HepG2 cells restored cleaved PINK1, Parkin, and LC3 protein levels, while reducing p62 expression, indicating that RNF126 promotes mitophagy. Furthermore, ROS fluorescence assays showed that RNF126 overexpression attenuated intracellular ROS accumulation. Rescue experiments demonstrated that the protective effects of RNF126 on mitochondrial membrane potential, lipid accumulation, and mitophagy marker expression are dependent on its ubiquitin ligase activity. Overall, RNF126 alleviates HFD-induced lipid accumulation and hepatic injury by promoting mitophagy and maintaining redox homeostasis, suggesting its potential as a novel therapeutic target for NAFLD.